Alzamend Neuro, INC

Alzamend Neuro, Inc. announced a $25 million securities purchase agreement for Series D convertible preferred stock and addressed Nasdaq's majority independent board standard non-compliance.

Alzamend Neuro, Inc. announced the passing of its director, Lynne Fahey McGrath, M.P.H., Ph.D., who died on July 20, 2026.

Stockholders of Alzamend Neuro, Inc. authorized a reverse stock split and approved a new 2025 Stock Incentive Plan during the annual meeting.

Alzamend Neuro, Inc. has entered into an At-the-Market Issuance Sales Agreement to sell up to $3.0 million of common stock.

Alzamend Neuro announced the passing of director Andrew H. Woo, M.D., Ph.D., who had served on the board since its 2021 IPO.

Alzamend Neuro, Inc. has officially eliminated its Series B and Series C convertible preferred stock designations, simplifying its capital structure.

Alzamend Neuro reported increased net losses and a 'going concern' warning, despite progress in its AL001 clinical trials and a recent capital raise.

Alzamend Neuro, a clinical-stage biopharmaceutical company, reported a significant increase in net loss for the quarter ended July 31, 2025, while advancing its AL001 clinical program and facing a going concern warning.

Alzamend Neuro announces its financial results for the third quarter of fiscal year 2025, highlighting ongoing clinical trials for AL001 and ALZN002, and recent financing activities to support operations.

Alzamend Neuro's Q2 2024 report shows a decrease in operating expenses and a net loss, while highlighting advancements in clinical trials and recent financing activities.

Alzamend Neuro reported a net loss of $974,411 for the quarter ended July 31, 2024, while advancing clinical trials and securing funding through preferred stock sales.

Alzamend Neuro's Q3 2024 report reveals a net loss of $2.7 million and ongoing efforts to secure additional funding for clinical trials.

Alzamend Neuro, Inc. filed its Form 10-K for the fiscal year ended April 30, 2026, detailing progress in its AL001 and ALZN002 clinical development programs and significant increases in operating expenses.

Alzamend Neuro's latest 10-K filing reveals significant financial challenges, including recurring losses and a going concern opinion, alongside a major delay in its ALZN002 Alzheimer's clinical trial, despite progress with its AL001 program.

Alzamend Neuro, Inc. has released its annual 10-K report, outlining its financial status, clinical trial progress, and future strategies for developing treatments for Alzheimers, bipolar disorder, major depressive disorder, and PTSD.

Director Milton C. Ault III acquired 108,388 shares of Alzamend Neuro, Inc. common stock through Ault Lending, LLC.

Alzamend Neuro Director Milton C. Ault III sold 1,851 shares of common stock to realize tax losses, maintaining significant indirect ownership.

Alzamend Neuro Director William B. Horne sold 3,333 shares of common stock at $2.1178 per share, reducing his direct beneficial ownership to zero.

Alzamend Neuro Director Lynne Fahey McGrath sold 30 shares of common stock at $2.29 per share on October 23, 2025.

Milton C. Ault III, a director at Alzamend Neuro, Inc., reported the conversion of preferred stock into common stock and subsequent sales of common stock.

Alzamend Neuro Director Milton C. Ault III reported multiple transactions in company stock, including conversions of preferred shares and open market sales, impacting his beneficial ownership.

Alzamend Neuro, Inc. announced its upcoming annual stockholders' meeting on April 17, 2026, to vote on director elections, auditor ratification, executive compensation, a new stock incentive plan, equity issuances, and a potential reverse stock split.

Alzamend Neuro, Inc. announces its 2026 Annual Meeting of Stockholders to vote on key proposals including a reverse stock split, a new equity incentive plan, and director elections.

Alzamend Neuro issues a second supplement to its proxy statement to correct a typographical error in the virtual meeting link for the 2025 annual stockholder meeting.

Alzamend Neuro files a supplement to its proxy statement to correct an error related to an adjournment proposal inadvertently included on the proxy card.

Alzamend Neuro is holding its 2025 Annual Meeting of Stockholders virtually on April 25, 2025, to vote on key proposals including the election of directors, ratification of auditors, approval of a stock conversion, and a potential reverse stock split.

Alzamend Neuro issues a supplement to its proxy statement, correcting the number of votes entitled to be cast at the upcoming special meeting of stockholders.

Alzamend Neuro is filing an amendment to its registration statement to allow a selling stockholder to resell up to 75,775,110 shares of common stock.

Alzamend Neuro files an S-1/A registration statement to resell up to 125 million shares of common stock, primarily for the benefit of Orchid Finance LLC.

Alzamend Neuro is registering for resale up to 125,000,000 shares of its common stock by Orchid Finance LLC, obtained through conversion of preferred shares and exercise of warrants.

Alzamend Neuro is registering for resale up to 125 million shares of common stock by Orchid Finance LLC, while also addressing ongoing Nasdaq listing compliance issues.

A Schedule 13D/A filing reveals significant insider selling by Ault Lending, LLC, an entity associated with Milton C. Ault, III, in Alzamend Neuro, Inc. common stock.

Milton C. Ault, III and affiliated entities updated their beneficial ownership in Alzamend Neuro, Inc., disclosing significant common stock sales by Ault Lending, LLC.

Milton C. Ault, III and affiliated entities have updated their beneficial ownership in Alzamend Neuro, Inc., disclosing significant share sales and conversions.

Milton C. Ault, III and affiliated entities collectively hold a 13.3% beneficial ownership in Alzamend Neuro, Inc., with Ault Lending, LLC converting preferred stock and selling common shares.

Milton C. Ault III and affiliated entities have updated their beneficial ownership in Alzamend Neuro, Inc., reporting a 15.9% stake and recent common stock sales.

Milton C. Ault, III and affiliated entities have updated their beneficial ownership in Alzamend Neuro, Inc., reporting a combined 18.5% stake and recent sales of common stock by Ault Lending, LLC.